Sarepta Therapeutics Faces Major Setback as Stock Plummets 35% After Second Fatality Linked to Gene Therapy

Sarepta Therapeutics (NASDAQ: SRPT) finds itself navigating some turbulent waters as its stock has recently taken a significant hit. The downturn follows reports of a second fatality linked to its gene therapy treatment, Elevidys, in a patient suffering from non-ambulatory Duchenne muscular dystrophy (DMD). As a consequence, Sarepta's shares saw a dramatic plunge, dropping nearly 35% in premarket trading.

Two prominent financial institutions, BMO Capital and Piper Sandler, have taken decisive actions in response to the developing situation. BMO has downgraded Sarepta's stock to "Market Perform," expressing serious concerns about the uncertainties surrounding the company. Meanwhile, Piper Sandler has lowered its rating to "Neutral," noting that this unfortunate incident could severely hamper both the adoption and commercial potential of Elevidys.

Despite Elevidys remaining on the market for ambulatory patients, broader safety concerns and increasing regulatory scrutiny are likely to exert downward pressure on the company's immediate prospects. In an effort to mitigate these risks, Sarepta has announced a suspension of commercial shipments of Elevidys in non-ambulatory cases and halted patient dosing in its ENVISION trial, which leaves traders contemplating the implications for future revenue streams.

The gravity of the situation was underlined by BMO, which remarked that while such adverse events are known risks associated with adenovirus-associated vector (AAV) gene therapies, the timing of the second death raises alarm bells among investors. Back in March, following the first linked death, Sarepta's shares already plummeted by 27%. Observers will be keeping a sharp eye on the company's guidance for 2025, particularly given the regulatory uncertainties that now loom large.

Piper Sandler has adjusted its price target for Sarepta from $55 down to $36, while also revising its peak sales estimates for Elevidys from $2.4 billion to $1.7 billion, a notable reduction. The brokerage emphasized the potential fallout that increased skepticism regarding the therapy may have on its utilization within the ambulatory population.

Sarepta is set to hold a conference call soon, aiming to provide more clarity on the current situation and its planned path forward. For stock traders closely monitoring the biotechnology sector, this is a significant moment that could define both short-term volatility and long-term strategy.

The question now remains for traders: will Sarepta's stock rebound, or are we looking at the beginning of a longer-term challenge for the DMD treatment pioneer? Only time will tell, but caution is undoubtedly the name of the game.